🩸 Pediatric Malignant Hyperthermia Recognition

Baseline Anesthesia in a RYR1-Susceptible Child

Malignant hyperthermia (MH) susceptibility is a pharmacogenetic trait, not a disease that is present at rest. A child carrying a pathogenic RYR1 variant has entirely normal muscle physiology until exposed to a triggering agent — which is exactly what makes MH so dangerous: nothing on a routine pre-op exam predicts the coming crisis.

• 1:5,000–1:50,000: MH incidence, general anesthesia (higher in children than adults)
• 19q13.1: RYR1 gene locus (ryanodine receptor 1)
• Autosomal dominant: Inheritance pattern (variable penetrance)
• ~50: Causative RYR1 variants known (of >700 identified)

Excitation-contraction coupling, working normally

In skeletal muscle, an action potential travels down the T-tubule and is sensed by the dihydropyridine receptor (DHPR), which is mechanically coupled to the ryanodine receptor (RyR1) on the sarcoplasmic reticulum (SR) membrane. Depolarization opens RyR1 briefly, releasing a calibrated pulse of Ca²⁺ into the cytosol to trigger one twitch. SERCA (sarco/endoplasmic reticulum Ca²⁺-ATPase) pumps then rapidly re-sequester that calcium, and the muscle relaxes.

In a child heterozygous for a pathogenic RYR1 mutation, this entire cycle looks completely normal at rest and under non-triggering anesthesia (propofol, opioids, nitrous oxide, non-depolarizing relaxants). The mutant channel has an abnormally low threshold for opening, but nothing pushes it past that threshold — until a triggering agent is given.

Who is at risk — screening before the first case

Because MH cannot be detected on routine exam or standard labs, risk stratification is almost entirely historical:

• Personal history of an unexplained intraoperative death, cardiac arrest, or "unexplained fever/rigidity" in a first-degree relative under general anesthesia • Known family RYR1 or CACNA1S pathogenic variant • Personal history of exertional heat illness, recurrent rhabdomyolysis, or unexplained elevated creatine kinase (CK) • Association with certain myopathies: central core disease and multiminicore disease (RYR1-linked) and King-Denborough syndrome carry a markedly elevated MH risk

Any of these should prompt a trigger-free (total intravenous) anesthetic plan and, where available, referral for contracture testing or genetic testing before an elective procedure — not testing during the emergency itself.

The triggering agents

Only two drug classes reliably trigger MH in a susceptible patient:

• Potent volatile anesthetics: halothane (highest risk, now rarely used), isoflurane, sevoflurane, desflurane • Depolarizing muscle relaxants: succinylcholine (also accelerates and intensifies a reaction already underway, and is the classic trigger of masseter muscle rigidity)

Nitrous oxide, all intravenous induction and maintenance agents (propofol, ketamine, etomidate, barbiturates), opioids, benzodiazepines, and non-depolarizing relaxants (rocuronium, vecuronium, cisatracurium) are NOT triggers and form the backbone of a trigger-free ("MH-safe") anesthetic for known-susceptible patients.

A prior uneventful general anesthetic with a volatile agent does NOT rule out MH susceptibility — penetrance is variable and a reaction can occur on any subsequent trigger exposure, including the second, third, or later anesthetic.

Uncontrolled Calcium Release from the Sarcoplasmic Reticulum

The molecular lesion in MH is disarmingly simple: a single abnormal calcium channel. Once a triggering agent reaches RyR1, the mutant gate opens and will not close normally, converting a self-limited calcium pulse into a sustained, unregulated flood.

• ~100 nM: Resting cytosolic [Ca²⁺] (tightly buffered normally)
• >1–10 µM: Triggered cytosolic [Ca²⁺] (10–100× resting level)
• ~90%: SR Ca²⁺ store (of total releasable pool)
• Minutes–hours: Onset after trigger exposure (may be delayed, even post-op)

RyR1: from calibrated valve to jammed floodgate

RyR1 is a homotetrameric channel — one of the largest known ion channel complexes — embedded in the SR membrane. Pathogenic RYR1 mutations (missense variants clustering in three "hotspot" regions of the gene) destabilize the closed state of the channel. In the presence of a volatile anesthetic or succinylcholine, the open probability of the mutant channel rises sharply and the normal, brief, self-terminating calcium pulse instead becomes sustained.

SERCA pumps attempt to recapture the escaping calcium, consuming large amounts of ATP in the process, but they are quickly overwhelmed: efflux through the jammed RyR1 channel outpaces reuptake by an order of magnitude.

This is a receptor-level problem, not a drug-overdose problem — MH can occur at entirely standard, weight-appropriate anesthetic doses. There is no dose of a triggering agent that is guaranteed to be safe in a genuinely susceptible patient.

Why succinylcholine is uniquely dangerous

Succinylcholine depolarizes the muscle membrane directly, which independently promotes RyR1 opening on top of any volatile-agent effect. This is why succinylcholine given after (or with) a volatile agent produces the fastest, most explosive reactions, and why isolated masseter muscle rigidity after succinylcholine is treated as a possible MH warning sign requiring close monitoring — of the children who develop marked masseter rigidity after succinylcholine, a substantial minority are subsequently confirmed MH-susceptible on contracture testing.

Calcium as the master signal

Cytosolic Ca²⁺ does not just trigger contraction — it is a signaling hub. Sustained high calcium simultaneously:

• Binds troponin C, holding the actin-myosin cross-bridge cycle continuously active • Activates calcium-dependent proteases (calpains), damaging the sarcolemma and contributing to later rhabdomyolysis • Activates phosphorylase kinase, accelerating glycogenolysis and glycolysis to fuel the runaway ATP demand • Stimulates mitochondrial Ca²⁺ uptake, uncoupling oxidative phosphorylation and further reducing ATP yield per unit of O₂ and substrate consumed

This is the molecular pivot point of the whole syndrome — everything downstream (heat, CO₂, acidosis, rigidity, rhabdomyolysis) is a direct consequence of calcium that cannot be turned back off.

The Hypermetabolic Cascade

With calcium locked in the "on" position, skeletal muscle — roughly 40% of a child's body mass — becomes a runaway metabolic engine. Oxygen consumption and CO₂ production surge, ATP is consumed faster than it can be regenerated, and the byproduct is heat: the defining, but late-appearing, feature that gives the syndrome its name.

• 2–3×: O₂ consumption increase (above baseline)
• 2–3×: CO₂ production increase (drives EtCO2 rise)
• Markedly ↑: ATP turnover (futile contraction-relaxation cycling)
• Mixed: Acid-base pattern (respiratory + metabolic (lactic) acidosis)

Futile cycling and the ATP crisis

Normally, ATP hydrolysis by myosin ATPase powers one productive contraction, and the muscle relaxes when calcium is resequestered. In MH, calcium never falls, so actin-myosin cross-bridges cycle continuously without net mechanical work — a "futile cycle" that converts chemical energy almost entirely into heat.

Simultaneously, SERCA pumps are burning ATP at maximal rate trying (and failing) to reverse the calcium leak. The cell attempts to keep pace via anaerobic glycolysis, generating lactate and hydrogen ions faster than they can be cleared, and via oxidative phosphorylation, generating CO₂ and consuming oxygen at 2–3 times the resting rate. Eventually ATP production cannot keep up with ATP consumption at all — this is the point at which muscle membrane integrity begins to fail.

Heat production — the last, not the first, sign

Heat is a byproduct of inefficient ATP turnover at the level of essentially every muscle fiber in the body simultaneously. Because skeletal muscle is such a large fraction of body mass, even modest per-fiber inefficiency sums to substantial whole-body heat generation. But heat takes time to accumulate and be sensed by a temperature probe — this is why hyperthermia is a late clinical sign, appearing well after the biochemical cascade (and after CO₂/tachycardia changes) has already begun.

By the time a child's temperature is clearly rising, the hypermetabolic cascade has usually been underway for many minutes already. Waiting for fever to make the diagnosis costs valuable time — EtCO2 and heart rate change first.

CO₂: the fastest-moving, most monitorable signal

CO₂ is produced by two simultaneous processes during the cascade: accelerated aerobic metabolism (oxidative CO₂) and buffering of the growing lactic acidosis by bicarbonate (metabolic CO₂). Both pour CO₂ into the blood, which is then delivered to the lungs and exhaled — making end-tidal CO₂ (EtCO2) an almost real-time, breath-by-breath readout of whole-body metabolic rate.

Because capnography is continuous and nearly instantaneous, a rising EtCO2 trend — especially one that persists or worsens after the anesthesia team increases minute ventilation to compensate — is detectable well before temperature, potassium, or visible rigidity change appreciably.

Early Clinical Signs — Reading the Vitals in Real Time

MH is recognized clinically before it is confirmed in a lab. The anesthesia team's earliest clues come entirely from the monitor and the surgical field: a capnograph trace and heart rate trend that will not behave, and — after succinylcholine — a jaw that will not open.

• ↑ EtCO2: Earliest, most sensitive sign (despite increased ventilation)
• >55–60 mmHg: EtCO2 in evolving MH (often climbing rapidly)
• ~1%: Masseter rigidity after succinylcholine (of children given succinylcholine + volatile)
• ~25–50%: MH confirmed on contracture testing (of marked masseter rigidity cases)

The single most sensitive early sign

A rise in end-tidal CO2 that is disproportionate to minute ventilation — or that persists despite the anesthesia team doubling minute ventilation to compensate — is widely regarded as the earliest and most sensitive intraoperative sign of MH. In a mechanically ventilated child, CO2 production normally scales predictably with ventilation; when it does not, and other causes have been quickly excluded, MH must be on the differential.

Tachycardia is often literally the first vital-sign change to appear, sometimes even before the EtCO2 trend is obvious — but heart rate is markedly nonspecific (light anesthesia, pain, fever, hypovolemia, and dozens of benign causes also cause tachycardia in children), so it raises suspicion without being diagnostic on its own.

Masseter muscle rigidity and generalized rigidity

Masseter muscle rigidity (trismus) after succinylcholine — jaw muscles that remain tightly contracted rather than relaxing — is a well-recognized red flag, particularly when severe ("jaws of steel") or accompanied by other changing vitals. Mild jaw tightening after succinylcholine is common and usually benign; marked, sustained rigidity is not.

Generalized skeletal muscle rigidity — limbs and trunk becoming diffusely rigid rather than relaxed under adequate anesthesia — is a stronger and more specific sign, reflecting the sustained actin-myosin cross-bridge cycling described in the hypermetabolic cascade. It typically appears alongside, or shortly after, the EtCO2 and heart rate changes.

Other early-window clues

A constellation of changes clusters in this window and should be interpreted together, not individually:

• Tachypnea in a spontaneously breathing child • Unstable or rising blood pressure • Mixed respiratory and metabolic acidosis on an early arterial blood gas • Skin mottling or unexpectedly warm skin • Decreasing oxygen saturation as metabolic demand outpaces delivery • Dark, desaturated-appearing blood in the surgical field (reflecting increased oxygen extraction)

No single item is diagnostic. The pattern — rising CO2 that resists ventilatory correction, tachycardia, and rigidity, evolving together and out of proportion to the surgical stimulus — is what should trigger the MH protocol.

A useful bedside rule: if EtCO2 keeps climbing after you have already increased minute ventilation to "fix" it, stop assuming it is a ventilation problem and start assuning it is a production problem.

Late Decompensation — Hyperthermia, Hyperkalemia, and Multi-Organ Threat

Left unrecognized, the hypermetabolic cascade rapidly outstrips the body's ability to compensate. Temperature climbs at a dramatic pace, cell membranes fail and release potassium and myoglobin into the circulation, and the combination becomes directly life-threatening within a short window of time.

• 1–2°C / 5 min: Core temperature rise rate (can exceed 42–46°C untreated)
• >6 mEq/L: Hyperkalemia threshold of concern (risk of malignant arrhythmia)
• >20,000 IU/L: Peak creatine kinase (CK) (confirms rhabdomyolysis (later lab))
• ~70–80%: Untreated mortality (historical) (vs <5% with prompt recognition + dantrolene)

Hyperthermia — rapid and self-accelerating

Once thermoregulation is overwhelmed, core temperature can rise 1–2°C every five minutes, with case reports documenting peaks above 42–46°C. This is not a passive fever — it directly worsens the underlying process: higher temperature accelerates enzyme kinetics and membrane instability, further increasing metabolic rate in a dangerous positive-feedback loop. Extreme hyperthermia alone can cause protein denaturation, coagulopathy, and irreversible neurologic injury independent of the other derangements.

Hyperkalemia and myoglobinuria — a failing membrane

Sustained calcium-dependent proteolysis (calpain activation) and ATP depletion compromise the sarcolemma. Damaged muscle cells release their intracellular contents into the circulation:

• Potassium: intracellular concentration is far higher than plasma; membrane failure causes rapid, sometimes severe hyperkalemia (>6 mEq/L), which is directly arrhythmogenic — peaked T waves, widened QRS, and ultimately ventricular fibrillation or asystole if uncorrected • Myoglobin: released from damaged myofibrils, filtered by the kidney, and visible at the bedside as dark, cola- or tea-colored urine — a classic and easily observed sign of rhabdomyolysis. Myoglobin is directly nephrotoxic and a major cause of acute kidney injury if the crisis is not reversed • Creatine kinase: rises over hours and is used to confirm rhabdomyolysis retrospectively, but is too slow to guide the acute intraoperative diagnosis

Hyperkalemic cardiac arrest can occur very rapidly once potassium release accelerates — in a child this can happen with frightening speed. Recognizing and treating the metabolic crisis early is what prevents ever reaching this point.

Arrhythmia, DIC, and multi-organ failure

The late phase can involve several simultaneous threats:

• Cardiac arrhythmias: driven by hyperkalemia, acidosis, and hyperthermia together — ranging from sinus tachycardia and ectopy to ventricular tachycardia, ventricular fibrillation, and cardiac arrest • Disseminated intravascular coagulation (DIC): extreme hyperthermia and tissue injury activate the coagulation cascade diffusely, consuming clotting factors and platelets — producing simultaneous oozing/bleeding from IV sites and the surgical field alongside microvascular thrombosis • Acute kidney injury: from myoglobin toxicity, hypoperfusion, and hyperthermia • Cerebral injury: extreme hyperthermia and hypoxia can cause lasting neurologic damage if the crisis is prolonged

These findings define fulminant MH and demand immediate, aggressive treatment (dantrolene sodium 2.5 mg/kg IV rapid bolus, repeated to a cumulative dose as needed, alongside aggressive cooling and correction of hyperkalemia/acidosis) — the detailed treatment-cart protocol and dantrolene dosing algorithm are the focus of a companion simulator; this one focuses on getting to the diagnosis fast enough for that protocol to matter.

Differentiating MH and Assessing Genetic Risk

Many benign and several other dangerous conditions can mimic isolated pieces of the MH picture — tachycardia, hypercapnia, or fever alone are common in the operating room. The diagnosis of MH rests on recognizing the specific combination and trajectory of signs, informed by pretest probability from family and personal history.

• 1-800-644-9737: MHAUS 24-hour hotline (US clinical consultation (N. America))
• ~97–99%: Contracture test (CHCT/IVCT) sensitivity (gold-standard muscle biopsy test)
• ~78–93%: Contracture test specificity (false positives occur)
• Limited: Accredited MH biopsy testing centers (few centers across North America/Europe)

Building the pattern, not chasing one number

Isolated tachycardia, isolated mild hypercapnia, or isolated low-grade fever are common and usually benign. MH becomes the leading diagnosis when several of the following are present together and worsening despite reasonable initial corrective steps:

• EtCO2 rising despite increased minute ventilation • Tachycardia out of proportion to surgical stimulus or depth of anesthesia • Masseter or generalized muscle rigidity • Rising core temperature, especially at a rapid rate • Mixed respiratory/metabolic acidosis on blood gas • Dark urine or laboratory evidence of rhabdomyolysis

The faster this combination is recognized, the sooner triggering agents can be stopped and dantrolene administered — the single intervention proven to reduce MH mortality.

Key differential diagnoses

Several other intraoperative problems can mimic parts of the MH picture and must be considered quickly, since correcting the wrong problem wastes critical time:

Genetic and family-history risk factors

RYR1 mutations follow autosomal dominant inheritance with variable, incomplete penetrance — a parent with a documented reaction has roughly a 50% chance of passing the variant to each child, but not every carrier will manifest a clinical event on every trigger exposure. CACNA1S mutations (encoding the DHPR) account for a smaller minority of confirmed MH-susceptible families.

Before any elective anesthetic, a focused family history should ask specifically about: unexplained intraoperative deaths, "unexplained" cardiac arrests under anesthesia, prior episodes of dark urine or rigidity after anesthesia, and known diagnoses of central core disease, multiminicore disease, or King-Denborough syndrome in relatives.

When suspicion is high, options include a trigger-free anesthetic by default (the safest and most practical approach for most families), referral for the caffeine-halothane contracture test (CHCT) / in vitro contracture test (IVCT) on a fresh muscle biopsy at an accredited center, or targeted genetic testing for known familial RYR1/CACNA1S variants once a proband has been identified.

A documented pathogenic RYR1 variant or a strongly suggestive family history is often sufficient to manage a child as MH-susceptible for anesthetic planning purposes — a normal contracture test in one relative does not clear other family members, and genetic testing without a known familial variant cannot fully exclude susceptibility.

MH vs. other causes of intraoperative tachycardia/hypercapnia